Home Infusion Therapy Market To Reach $28.3 Billion By 2024
The global home infusion therapy market is expected to reach USD 28.3 billion by 2024, according to a new report by Grand View Research, Inc. The rising significance of costcontainment in home infusion in comparison with in-patient settings is a high-impact rendering driver of the home infusion therapy market. Moreover, long-term cost savings in the treatment of chronic diseases associated with the home infusion therapy is primarily driving the growth of the industry during the forecast period. As per a study published in NCBI in 2011, a cost containment program targets cost reduction and study associated patient’s preference pattern changes towards home infusion therapy. As per this study, a short-term reduction of over USD 2,247 in costs was achieved and a reduction of longterm costs of over USD 10,424 too, illustrating that significant cost reductions can be achieved through the incorporation of home infusion therapy. Moreover, the rising penetration rate of home and alternate site services as a consequence of high patient preference due to the high awareness & recognition of benefits associated with the aforementioned are presumed to propel the growth of home infusion therapy market over the forecast period. Furthermore, an extensive pipeline of infusible drugs as a result of high R&D investment by global market players is a key contributing factor towards presenting the home infusion therapy market with lucrative growth opportunities during the forecast period.